Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 16 2024 - 4:30PM
Esperion (NASDAQ: ESPR) today announced that, on February 13, 2024,
the Company granted 66 new employees 204,900 restricted stock units
(RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is used
exclusively for the grant of equity awards to individuals who were
not previously an employee or non-employee director of Esperion (or
following a bona fide period of non-employment), as an inducement
material to such individual's entering into employment with
Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing
Rules.
Each RSU will vest and become exercisable as to 25
percent of the shares on the one-year anniversary of the
recipient’s vesting commencement date and will vest and become
exercisable as to the remaining 75 percent of the shares in twelve
equal quarterly installments at the end of each quarter following
such anniversary, in each case, subject to each such employee's
continued employment with Esperion on such vesting dates. The RSUs
are subject to the terms and conditions of Esperion’s 2017
Inducement Equity Incentive Plan, and the terms and conditions of
the RSU agreement covering the grant.
Esperion TherapeuticsAt Esperion,
we discover, develop, and commercialize innovative medicines to
help improve outcomes for patients with or at risk for
cardiovascular and cardiometabolic diseases. The status quo is not
meeting the health needs of millions of people with high
cholesterol – that is why our team of passionate industry leaders
is breaking through the barriers that prevent patients from
reaching their goals. Providers are moving toward reducing
LDL-cholesterol levels as low as possible, as soon as possible; we
provide the next steps to help get patients there. Because when it
comes to high cholesterol, getting to goal is not optional. It is
our life’s work. For more information, visit esperion.com and
esperionscience.com and follow us on Twitter at
twitter.com/EsperionInc.
Esperion Contact
Information:Investors:Alexis
Callahaninvestorrelations@esperion.com(406) 539-1762
Media:Tiffany
Aldrichcorporateteam@esperion.com(616) 443-8438
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2024 to Jun 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2023 to Jun 2024